Gesynta Pharma Raises $29M to Advance Non-Hormonal Endometriosis Treatment Femtech Insider
GSK’s Jemperli gains EU approval for advanced endometrial cancer treatment DirectorsTalk Interviews
GSK’s Jemperli Gains Expanded EU Approval for Broader Endometrial Cancer Treatment TipRanks
GSK’s Jemperli wins EU nod for broader use in front-line endometrial cancer FirstWord Pharma
Endometriosis poses substantial burden on Australia's health system MSN
Currently, hormonal therapy for endometriosis faces challenges in achieving a balance between treatment and preserving the chance of pregnancy. Therefore, the development of non-hormonal therapy holds significant clinical importance. Angiogenesis …
Heterotaxia is characterized by an abnormal positioning of the thoracic and/or abdominal organs, resulting in various physiological and hemodynamic implications. Congenital heart disease involves structural irregularities in the heart or …
The dynamic nature of human endometrial tissue presents unique challenges in analysis. Despite extensive research into endometrial disorders such as endometriosis and infertility, recent systematic reviews have highlighted concerning issues …
Endometriosis is a widely spread disease that affects about 8% of the world's female population. This condition may be described as a spread of endometrial tissue apart from the uterine …
What is the hormone receptor profile of adenomyosis lesions in comparison to correctly located endometrium?